Recurrent UTI prevention — what the supplement evidence supports
Last reviewed
For recurrent UTI (two or more in six months, or three or more in a year), supplements are for prevention between episodes, not treatment of an active infection, which needs a clinician and usually antibiotics. D-mannose at 2 g/day does not have that prevention benefit in the best trial we have: the 2024 MERIT randomised trial (Hayward and colleagues, JAMA Internal Medicine, PMID 38497963) of 598 women in UK primary care found no significant reduction in further UTIs versus placebo. Earlier, smaller trials had suggested a benefit comparable to low-dose antibiotics; those studies were lower quality, and this guide follows MERIT. PAC-standardised cranberry, but only at or above 36 mg proanthocyanidins per day, is the supplement option with prevention evidence (most juices and capsules fall short). In postmenopausal women, prescription vaginal estrogen outperforms every supplement and is the first conversation to have. Fever or flank pain signals a kidney infection needing urgent care. Skip plain cranberry juice, colloidal silver, and chronic uva ursi.
Read this first. Active UTI symptoms — burning urination, urgency, frequency, suprapubic pain — need clinician assessment, urine culture where indicated, and antibiotic treatment. Supplements are for prevention in known recurrent-UTI patients between episodes, not for treating an active infection. Symptoms suggesting upper-tract involvement (fever, flank pain, vomiting) need urgent care, not supplement self-management. Pregnancy UTI is a separate, urgent conversation.
The supplements with the strongest prevention evidence
Cranberry extract (PAC-standardised, ≥36 mg PAC/day)
36 mg proanthocyanidins (PAC) per day from a standardised extract — this is the trial-validated threshold
The cranberry literature is messier than the marketing suggests. The active compounds are A-type proanthocyanidins (PACs), which inhibit bacterial adhesion. The dose threshold matters: trials below 36 mg PAC/day are typically null; trials at or above the threshold are typically positive in cohort and prevention RCTs. The 2023 Cochrane review confirmed prevention benefit in women with recurrent UTI. Cranberry juice and most consumer cranberry capsules deliver too little PAC at standard servings — look explicitly for products that disclose PAC content (Ellura is a commonly-cited example at 36 mg PAC/capsule).
Vaginal estrogen (prescription)
Topical estradiol cream, ring, or tablet — clinician-prescribed
Not a supplement, but worth listing because it has substantially better recurrent-UTI prevention evidence than any supplement in postmenopausal women. The mechanism — restoring vaginal lactobacillus colonisation and reducing periurethral colonisation by uropathogens — is well-established. Local (vaginal) estrogen does not carry the systemic risks of oral hormone therapy. If you are postmenopausal with recurrent UTI, this is the conversation to have first.
The supplements with smaller-but-suggestive evidence
- Lactobacillus probiotics (specific strains: L. rhamnosus GR-1, L. reuteri RC-14) — small studies in oral or intravaginal protocols. The evidence base is thinner than cranberry. The two named strains have the most-cited UTI-specific data; generic "women's probiotic" products typically do not include them at trial-validated doses.
- Vitamin D3 (in deficient patients) — observational associations between low 25-OH-D and recurrent UTI. Reasonable to replete deficiency for general health reasons; UTI-specific trial evidence is preliminary.
- Methenamine hippurate — not a supplement (OTC in some jurisdictions, prescription in others). The 2022 ALTAR trial established it as non-inferior to antibiotic prophylaxis for recurrent UTI prevention, with substantially less antibiotic resistance. Worth knowing about and asking your clinician.
D-mannose after the 2024 trial
D-mannose
A large 2024 trial found no benefit for preventing recurrent UTIs.
D-mannose is a simple sugar that can bind the FimH adhesin on uropathogenic E. coli, the bacterium responsible for most community-acquired UTIs. That mechanism is real. The clinical result is not: the MERIT trial (Hayward 2024, JAMA Internal Medicine, PMID 38497963; 598 women in UK primary care) found D-mannose did not significantly reduce recurrent UTIs versus placebo. Earlier small trials had suggested a benefit comparable to low-dose antibiotics. Those trials were smaller and lower quality, and this page follows MERIT rather than them. It is generally well tolerated, with mild osmotic stomach effects at higher doses. There is limited data in pregnancy; discuss any use with your obstetric clinician. Do not use it to treat an active infection.
What to skip
- Plain cranberry juice — typically PAC content too low at any reasonable serving; sugar load substantial; no consistent benefit in trials.
- Generic "urinary tract support" multi-ingredient products — combine sub-therapeutic doses of cranberry, D-mannose, hibiscus, and others.
- Uva ursi (bearberry) for chronic use — short-term efficacy for active symptoms is suggested in old literature, but contains hydroquinone which is hepatotoxic and potentially carcinogenic with chronic use. Not for prevention.
- Hibiscus tea (high-dose extracts) — limited evidence and theoretical antiplatelet concerns at high doses.
- "Alkaline" urine cleanses — alkalinisation does not improve outcomes in most UTI scenarios; the popular potassium citrate / sodium bicarbonate protocols carry their own electrolyte risks.
- Colloidal silver — no evidence, real risk of permanent skin discoloration (argyria).
The non-supplement layer that matters
Several behavioural and clinical interventions have meaningful UTI-prevention evidence: post-coital voiding (small but consistent effect in women whose UTIs are sex-related), adequate fluid intake (the 2018 RCT of an extra 1.5 L/day in women with low baseline fluid intake reduced recurrence by ~50%), front-to-back wiping, avoiding spermicide-based contraception (associated with higher UTI rates). Daily prophylactic antibiotics work but build resistance and are increasingly disfavoured for long-term use. Methenamine hippurate is a reasonable non-antibiotic prescription alternative.
What to track
UTI episode count over 6-month windows. If recurrence persists despite supplement and lifestyle measures at 6 months, the conversation with urology or your primary care physician should consider methenamine hippurate, vaginal estrogen (postmenopausal), or imaging to rule out anatomic contributors.
Practical quick-start. PAC-standardised cranberry (≥36 mg PAC/day) + adequate hydration (target 2.5+ L/day) + behavioural measures. Do not add D-mannose on the strength of the older antibiotic-comparison trials; the 2024 MERIT trial found no benefit at 2 g/day. Reassess at 3 months. If postmenopausal, the first conversation with your clinician is vaginal estrogen — it tends to outperform every supplement in that population.